Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control

S. H. Md Isa, I. Najihah, W. M Wan Nazaimoon, Nor Azmi Kamaruddin, N. A. Umar, N. H. Mat, B. A K Khalid

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We studied the efficacy of four different treatment regimens (sulphonylurea and metformin ± acarbose versus glimepiride and rosiglitazone versus glimepiride and bedtime NPH insulin versus multiple actrapid and NPH insulin injections) in poorly controlled type 2 diabetes subjects on hs-CRP, VCAM-1 and AGE at 4, 8 and 12 weeks of treatment. Multiple insulin injections rapidly improved HbA1c by 0.6 ± 0.9% (p < 0.005), 1.2 ± 1.3% (p < 0.0005) and 1.3 ± 1.4% (p < 0.0005) at week 4, at week 8 and week 12, respectively. Subjects who continued their existing combination treatment of sulphonylurea, metformin ± acarbose also showed a significant reduction in HbA1c (p < 0.05). Although effective in reducing glycemic parameters, there was no reduction in CRP levels in either treatment group. The treatment regimen consisting of rosiglitazone and glimepiride significantly lowered hs-CRP by -2.6 (3.9) mg/L (p < 0.05) at week 12 in spite of no improvement in blood glucose. AGE improved in all groups irrespective of type of treatment, glycaemic control and CRP levels. Our data indicate rapid glycaemic control alone does not necessarily result in improvement in markers of inflammation in type 2 diabetes patients.

Original languageEnglish
Pages (from-to)48-52
Number of pages5
JournalDiabetes Research and Clinical Practice
Volume72
Issue number1
DOIs
Publication statusPublished - Apr 2006

Fingerprint

Advanced Glycosylation End Products
glimepiride
Glycosylation
C-Reactive Protein
rosiglitazone
Glucose
Isophane Insulin
Acarbose
neutral insulin
Metformin
Type 2 Diabetes Mellitus
Therapeutics
Injections
Vascular Cell Adhesion Molecule-1
Blood Glucose
Insulin
Inflammation

Keywords

  • Adhesion molecules
  • Advanced glycosylation end-products (AGE)
  • C-reactive protein
  • Glycaemic control
  • Type 2 diabetes

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. / Md Isa, S. H.; Najihah, I.; Nazaimoon, W. M Wan; Kamaruddin, Nor Azmi; Umar, N. A.; Mat, N. H.; Khalid, B. A K.

In: Diabetes Research and Clinical Practice, Vol. 72, No. 1, 04.2006, p. 48-52.

Research output: Contribution to journalArticle

Md Isa, S. H. ; Najihah, I. ; Nazaimoon, W. M Wan ; Kamaruddin, Nor Azmi ; Umar, N. A. ; Mat, N. H. ; Khalid, B. A K. / Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control. In: Diabetes Research and Clinical Practice. 2006 ; Vol. 72, No. 1. pp. 48-52.
@article{0078160861d94db8b5a61dfdf0f16ad8,
title = "Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control",
abstract = "We studied the efficacy of four different treatment regimens (sulphonylurea and metformin ± acarbose versus glimepiride and rosiglitazone versus glimepiride and bedtime NPH insulin versus multiple actrapid and NPH insulin injections) in poorly controlled type 2 diabetes subjects on hs-CRP, VCAM-1 and AGE at 4, 8 and 12 weeks of treatment. Multiple insulin injections rapidly improved HbA1c by 0.6 ± 0.9{\%} (p < 0.005), 1.2 ± 1.3{\%} (p < 0.0005) and 1.3 ± 1.4{\%} (p < 0.0005) at week 4, at week 8 and week 12, respectively. Subjects who continued their existing combination treatment of sulphonylurea, metformin ± acarbose also showed a significant reduction in HbA1c (p < 0.05). Although effective in reducing glycemic parameters, there was no reduction in CRP levels in either treatment group. The treatment regimen consisting of rosiglitazone and glimepiride significantly lowered hs-CRP by -2.6 (3.9) mg/L (p < 0.05) at week 12 in spite of no improvement in blood glucose. AGE improved in all groups irrespective of type of treatment, glycaemic control and CRP levels. Our data indicate rapid glycaemic control alone does not necessarily result in improvement in markers of inflammation in type 2 diabetes patients.",
keywords = "Adhesion molecules, Advanced glycosylation end-products (AGE), C-reactive protein, Glycaemic control, Type 2 diabetes",
author = "{Md Isa}, {S. H.} and I. Najihah and Nazaimoon, {W. M Wan} and Kamaruddin, {Nor Azmi} and Umar, {N. A.} and Mat, {N. H.} and Khalid, {B. A K}",
year = "2006",
month = "4",
doi = "10.1016/j.diabres.2005.09.011",
language = "English",
volume = "72",
pages = "48--52",
journal = "Diabetes Research and Clinical Practice",
issn = "0168-8227",
publisher = "Elsevier Ireland Ltd",
number = "1",

}

TY - JOUR

T1 - Improvement in C-reactive protein and advanced glycosylation end-products in poorly controlled diabetics is independent of glucose control

AU - Md Isa, S. H.

AU - Najihah, I.

AU - Nazaimoon, W. M Wan

AU - Kamaruddin, Nor Azmi

AU - Umar, N. A.

AU - Mat, N. H.

AU - Khalid, B. A K

PY - 2006/4

Y1 - 2006/4

N2 - We studied the efficacy of four different treatment regimens (sulphonylurea and metformin ± acarbose versus glimepiride and rosiglitazone versus glimepiride and bedtime NPH insulin versus multiple actrapid and NPH insulin injections) in poorly controlled type 2 diabetes subjects on hs-CRP, VCAM-1 and AGE at 4, 8 and 12 weeks of treatment. Multiple insulin injections rapidly improved HbA1c by 0.6 ± 0.9% (p < 0.005), 1.2 ± 1.3% (p < 0.0005) and 1.3 ± 1.4% (p < 0.0005) at week 4, at week 8 and week 12, respectively. Subjects who continued their existing combination treatment of sulphonylurea, metformin ± acarbose also showed a significant reduction in HbA1c (p < 0.05). Although effective in reducing glycemic parameters, there was no reduction in CRP levels in either treatment group. The treatment regimen consisting of rosiglitazone and glimepiride significantly lowered hs-CRP by -2.6 (3.9) mg/L (p < 0.05) at week 12 in spite of no improvement in blood glucose. AGE improved in all groups irrespective of type of treatment, glycaemic control and CRP levels. Our data indicate rapid glycaemic control alone does not necessarily result in improvement in markers of inflammation in type 2 diabetes patients.

AB - We studied the efficacy of four different treatment regimens (sulphonylurea and metformin ± acarbose versus glimepiride and rosiglitazone versus glimepiride and bedtime NPH insulin versus multiple actrapid and NPH insulin injections) in poorly controlled type 2 diabetes subjects on hs-CRP, VCAM-1 and AGE at 4, 8 and 12 weeks of treatment. Multiple insulin injections rapidly improved HbA1c by 0.6 ± 0.9% (p < 0.005), 1.2 ± 1.3% (p < 0.0005) and 1.3 ± 1.4% (p < 0.0005) at week 4, at week 8 and week 12, respectively. Subjects who continued their existing combination treatment of sulphonylurea, metformin ± acarbose also showed a significant reduction in HbA1c (p < 0.05). Although effective in reducing glycemic parameters, there was no reduction in CRP levels in either treatment group. The treatment regimen consisting of rosiglitazone and glimepiride significantly lowered hs-CRP by -2.6 (3.9) mg/L (p < 0.05) at week 12 in spite of no improvement in blood glucose. AGE improved in all groups irrespective of type of treatment, glycaemic control and CRP levels. Our data indicate rapid glycaemic control alone does not necessarily result in improvement in markers of inflammation in type 2 diabetes patients.

KW - Adhesion molecules

KW - Advanced glycosylation end-products (AGE)

KW - C-reactive protein

KW - Glycaemic control

KW - Type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=33645280894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645280894&partnerID=8YFLogxK

U2 - 10.1016/j.diabres.2005.09.011

DO - 10.1016/j.diabres.2005.09.011

M3 - Article

C2 - 16253380

AN - SCOPUS:33645280894

VL - 72

SP - 48

EP - 52

JO - Diabetes Research and Clinical Practice

JF - Diabetes Research and Clinical Practice

SN - 0168-8227

IS - 1

ER -